When An “Abysmal” Study Is Good Enough: Avedro CXL Therapy Clears FDA Committee
This article was originally published in RPM Report
Executive Summary
Avedro Inc.’s CXL drug/device combination therapy for corneal cross-linking is not your typical new drug application. But a February advisory committee discussion of the application helps show the contours of the current regulatory climate for innovators at FDA.